© 2021 MJH Life Sciences and HCPLive. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive. All rights reserved.
January 19, 2021
A phase 2 study suggests treating the common diabetes comorbidity may be capable with the monoclonal antibody.
January 14, 2021
The SOLOIST-WHF trial indicates that SGLT2 inhibition may lead to an overall reduction in cardiovascular-related deaths and hospitalizations.
A new study finds benefit to hemoglobin A1c reductions made following conception.
January 12, 2021
The study finds that individuals with mothers who had pregestational diabetes had a 2.3-fold increased risk of MS compared to those with non-diabetic mothers.
Obese or overweight men participating in a lifestyle-based program had lower rates of diabetes after 2 years when also given testosterone therapy, a new study finds.
January 08, 2021
If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.
January 04, 2021
The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.
December 29, 2020
The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.
December 14, 2020
Amputations have increased 30% among diabetic patients since the pandemic began.